Document 0673
 DOCN  M9590673
 TI    Cofactors, coreceptors, and new retroviruses. An interview with Robin A
       Weiss, PhD. [interview by Mark Mascolini] Clearinghouse, P.O. Box 6003,
       Rockville, MD 20849-6003. 800-458-5231 ext. 5023.
 DT    9509
 AU    Weiss RA
 SO    J Int Assoc Physicians AIDS Care. 1995 Feb;1(1):6-10. Unique Identifier
       : AIDSLINE AIDS/95700205
 AB    Dr. Robin A. Weiss, Director of Research at the Chester Beatty
       Laboratories of the Institute of Cancer Research in London, England
       presents his thoughts on the subjects of cofactors, coreceptors, and new
       retroviruses in HIV infection. Dr. Weiss responds to questions in the
       following areas: balancing basic research and clinical trials, the
       importance of sheer viral load, the importance of pathogenic cofactors
       in HIV progression, genetic factors and susceptibility to HIV, possible
       reasons for long-term nonprogression, the importance of immunotherapy,
       the difficulty in finding a second receptor as a cofactor necessary for
       disease progression, and whether more human retroviruses are likely to
       be discovered. Among Weiss' observations are his beliefs that there
       should be more of a funding shift into basic research, that evidence is
       getting stronger for the theory that beating back the viral burden as
       soon as possible forestalls progression, that it appears possible that
       some people may have a genetic disposition against becoming HIV
       infected, that it is just as important to find a preinfection vaccine as
       it is a post-infection vaccine, and his belief that CD26 is not a
       coreceptor in AIDS progression.
 DE    Disease Susceptibility/GENETICS  HIV/ISOLATION & PURIF/*PHYSIOLOGY  HIV
       Infections/GENETICS/PHYSIOPATHOLOGY/THERAPY  Human  Immunotherapy
       Receptors, Virus/*PHYSIOLOGY  Survivors  Viremia  NEWSLETTER ARTICLE
       INTERVIEW

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).